These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39120847)

  • 1. Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA.
    Strand V; Bender S; McCabe D
    Rheumatol Ther; 2024 Oct; 11(5):1291-1302. PubMed ID: 39120847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA.
    Strand V
    Rheumatol Ther; 2024 Oct; 11(5):1081-1084. PubMed ID: 39120850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
    Strand V; Boklage SH; Kimura T; Joly F; Boyapati A; Msihid J
    Arthritis Res Ther; 2020 Oct; 22(1):250. PubMed ID: 33081825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
    Bartlett SJ; Bingham CO; van Vollenhoven R; Murray C; Gruben D; Gold DA; Cella D
    Arthritis Res Ther; 2022 Apr; 24(1):83. PubMed ID: 35382883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.
    Strand V; Sharp V; Koenig AS; Park G; Shi Y; Wang B; Zack DJ; Fiorentino D
    Ann Rheum Dis; 2012 Jul; 71(7):1143-50. PubMed ID: 22258482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
    Strand V; Tundia N; Bergman M; Ostor A; Durez P; Song IH; Enejosa J; Schlacher C; Song Y; Fleischmann R
    Rheumatology (Oxford); 2021 Dec; 60(12):5583-5594. PubMed ID: 33590829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials.
    Citera G; Jain R; Irazoque F; Madariaga H; Gruben D; Wang L; Stockert L; Santana K; Ebrahim A; Ponce de Leon D
    Rheumatol Ther; 2024 Feb; 11(1):35-50. PubMed ID: 37925660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.
    Strand V; Michalska M; Birchwood C; Pei J; Tuckwell K; Finch R; Gabay C; Kavanaugh A; Jones G
    RMD Open; 2017; 3(2):e000496. PubMed ID: 28955499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.
    Kang J; Eudy-Byrne RJ; Mondick J; Knebel W; Jayadeva G; Liesenfeld KH
    Br J Clin Pharmacol; 2020 Nov; 86(11):2274-2285. PubMed ID: 32363771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plain language summary of the VOLTAIRE-RA in patients with moderate-to-severe rheumatoid arthritis.
    Cohen SB; Lee EC
    Immunotherapy; 2022 Oct; 14(15):1183-1190. PubMed ID: 36065786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext).
    Cohen SB; Czeloth N; Lee E; Klimiuk PA; Peter N; Jayadeva G
    Expert Opin Biol Ther; 2019 Oct; 19(10):1097-1105. PubMed ID: 31387417
    [No Abstract]   [Full Text] [Related]  

  • 13. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
    Strand V; Mease PJ; Soriano ER; Kishimoto M; Salvarani C; Saffore CD; Zueger P; McDearmon-Blondell E; Kato K; Gladman DD
    Rheumatol Ther; 2021 Dec; 8(4):1789-1808. PubMed ID: 34636026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases.
    Bhat S; Patel M; Duly K; Choi D
    Ann Pharmacother; 2022 Dec; 56(12):1356-1364. PubMed ID: 35392668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
    Strand V; Schiff M; Tundia N; Friedman A; Meerwein S; Pangan A; Ganguli A; Fuldeore M; Song Y; Pope J
    Arthritis Res Ther; 2019 Dec; 21(1):263. PubMed ID: 31791386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Strand V; Pope J; Tundia N; Friedman A; Camp HS; Pangan A; Ganguli A; Fuldeore M; Goldschmidt D; Schiff M
    Arthritis Res Ther; 2019 Dec; 21(1):272. PubMed ID: 31815649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B
    Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study.
    Strand V; Burmester GR; Ogale S; Devenport J; John A; Emery P
    Rheumatology (Oxford); 2012 Oct; 51(10):1860-9. PubMed ID: 22753773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.